Advances in vaccine adjuvants
暂无分享,去创建一个
[1] G. Dougan,et al. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. , 1999, Immunology today.
[2] N. Lycke,et al. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. , 1999, Journal of immunology.
[3] N. Lycke,et al. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. , 1999, Journal of immunology.
[4] K. Barnhart,et al. CpG motifs as immune adjuvants. , 1999, Vaccine.
[5] D. Putnam,et al. PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. , 1999, Journal of pharmaceutical sciences.
[6] E. Gelfand,et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. , 1998, Journal of immunology.
[7] P. Ricciardi-Castagnoli,et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.
[8] M. Rothe,et al. Human Toll-like Receptor 2 Confers Responsiveness to Bacterial Lipopolysaccharide , 1998, The Journal of experimental medicine.
[9] O’Hagan,et al. Microparticles and polymers for the mucosal delivery of vaccines. , 1998, Advanced drug delivery reviews.
[10] H. Mischak,et al. CpG‐DNA‐specific activation of antigen‐presenting cells requires stress kinase activity and is preceded by non‐specific endocytosis and endosomal maturation , 1998, The EMBO journal.
[11] H. Davis,et al. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. , 1998, Journal of immunology.
[12] A. Gurney,et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling , 1998, Nature.
[13] T. Jakob,et al. Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. , 1998, Journal of immunology.
[14] C. Kensil,et al. QS-21: a water-soluble triterpene glycoside adjuvant. , 1998, Expert opinion on investigational drugs.
[15] I. Barr,et al. ISCOMs and other saponin based adjuvants. , 1998, Advanced drug delivery reviews.
[16] M. S. Singh,et al. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. , 1998, Advanced drug delivery reviews.
[17] Gupta,et al. Aluminum compounds as vaccine adjuvants. , 1998, Advanced drug delivery reviews.
[18] Wang,et al. Targeting immune response induction with cochleate and liposome-based vaccines. , 1998, Advanced drug delivery reviews.
[19] Newman,et al. Development of adjuvant-active nonionic block copolymers. , 1998, Advanced drug delivery reviews.
[20] T. Wilckens. Steroid Hormones and the T-cell Cytokine Profile , 1998 .
[21] Z. Moldoveanu,et al. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. , 1998, Vaccine.
[22] R. Vabulas,et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells , 1998, European journal of immunology.
[23] M. Salgaller,et al. Use of cellular and cytokine adjuvants in the immunotherapy of cancer , 1998, Journal of surgical oncology.
[24] H. Mohri,et al. Induction of Systemic and Mucosal Immune Responses to Human Immunodeficiency Virus Type 1 by a DNA Vaccine Formulated with QS-21 Saponin Adjuvant via Intramuscular and Intranasal Routes , 1998, Journal of Virology.
[25] D. McDonald,et al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. , 1998, Cellular immunology.
[26] G. Dougan,et al. Optimism over vaccines administered via mucosal surfaces , 1998, The Lancet.
[27] R. Gupta,et al. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. , 1998, Vaccine.
[28] M. Levine,et al. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato , 1998, Nature Medicine.
[29] J. Sprent,et al. DNA as an Adjuvant: Capacity of Insect DNA and Synthetic Oligodeoxynucleotides to Augment T Cell Responses to Specific Antigen , 1998, The Journal of experimental medicine.
[30] G. Dougan,et al. Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of Escherichia coli Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity , 1998, The Journal of experimental medicine.
[31] O’Hagan,et al. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: the effect of adjuvants on mucosal and serum antibody responses , 1998, Immunology.
[32] P. van Damme,et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. , 1998, Vaccine.
[33] B. Hirst,et al. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo. , 1998, Vaccine.
[34] M. Hedley,et al. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses , 1998, Nature Medicine.
[35] G. Matyas,et al. Skin immunization made possible by cholera toxin , 1998, Nature.
[36] Scott D. Putney,et al. Improving protein therapeutics with sustained-release formulations , 1998, Nature Biotechnology.
[37] A. Krieg,et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. , 1998, Journal of immunology.
[38] J. Orange,et al. Early Murine Cytomegalovirus (MCMV) Infection Induces Liver Natural Killer (NK) Cell Inflammation and Protection Through Macrophage Inflammatory Protein 1α (MIP-1α)–dependent Pathways , 1998, The Journal of experimental medicine.
[39] A. Andrianov,et al. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. , 1998, Vaccine.
[40] G. Dougan,et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. , 1998, Vaccine.
[41] M. Reddish,et al. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 , 1998, Nature Medicine.
[42] R. Rappuoli,et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection , 1997, Infection and immunity.
[43] G. Van Nest,et al. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. , 1997, Vaccine.
[44] A. Hill,et al. A protein particle vaccine containing multiple malaria epitopes , 1997, Nature Biotechnology.
[45] J. Berzofsky,et al. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[46] A. Holder,et al. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. , 1997, Vaccine.
[47] T. Monath,et al. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins , 1997, Infection and immunity.
[48] K. Okuda,et al. HIV‐1‐specific cell‐mediated immune responses induced by DNA vaccination were enhanced by mannan‐coated liposomes and inhibited by anti‐interferon‐γ antibody , 1997, Immunology.
[49] H. Mohri,et al. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1 , 1997, Infection and immunity.
[50] F Ambrosch,et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. , 1997, Vaccine.
[51] C. Janeway,et al. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.
[52] H. Weiner. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. , 1997, Immunology today.
[53] G. Dougan,et al. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin , 1997, Infection and immunity.
[54] J. Clegg,et al. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. , 1997, Vaccine.
[55] D. Granoff,et al. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine , 1997, Infection and immunity.
[56] N. Lycke,et al. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit. , 1997, Journal of immunology.
[57] A. Osterhaus,et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. , 1997, The Journal of general virology.
[58] Donald E. Chickering,et al. Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.
[59] P. Couvreur,et al. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres , 1997, Infection and immunity.
[60] D. Rahman,et al. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles. , 1997, Vaccine.
[61] G. Ott,et al. Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. , 1997, Molecular medicine today.
[62] Joe D. Cohen,et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.
[63] R. Rappuoli,et al. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop , 1997, Infection and immunity.
[64] R. Langer,et al. Polymerized liposomes as potential oral vaccine carriers: Stability and bioavailability , 1996 .
[65] O'Hagan Dt,et al. THE INTESTINAL UPTAKE OF PARTICLES AND THE IMPLICATIONS FOR DRUG AND ANTIGEN DELIVERY , 1996 .
[66] G. Nest,et al. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. , 1996, The Journal of infectious diseases.
[67] X M Li,et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. , 1996, Vaccine.
[68] J. Whittum-Hudson,et al. Oral immunization with an anti–idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection , 1996, Nature Medicine.
[69] L. Bergmeier,et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes. , 1996, Journal of immunology.
[70] J. Carlson,et al. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. , 1996, Vaccine.
[71] G. Dougan,et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant , 1996, Infection and immunity.
[72] B. McBride,et al. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection , 1996, Infection and immunity.
[73] C. Kensil. Saponins as vaccine adjuvants. , 1996, Critical reviews in therapeutic drug carrier systems.
[74] D. O’hagan. The intestinal uptake of particles and the implications for drug and antigen delivery. , 1996, Journal of anatomy.
[75] D. Ruble,et al. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres , 1995, Infection and immunity.
[76] C. Dekker,et al. A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy , 1995, Annals of Internal Medicine.
[77] J. Clements,et al. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity , 1995, Infection and immunity.
[78] G. Bishop,et al. CpG motifs in bacterial DNA trigger direct B-cell activation , 1995, Nature.
[79] J. Eldridge,et al. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres , 1995, Infection and immunity.
[80] G. Dougan,et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[81] J. T. Ulrich,et al. Monophosphoryl Lipid A as an Adjuvant , 1995 .
[82] K. Mills,et al. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. , 1995, Vaccine.
[83] R. Wagner,et al. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens. , 1995, Vaccine.
[84] K. Mills,et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. , 1995, Vaccine.
[85] H. Okada,et al. Biodegradable microspheres in drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.
[86] C. Kensil,et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. , 1995, Vaccine.
[87] F. Vogel,et al. A compendium of vaccine adjuvants and excipients. , 1995, Pharmaceutical biotechnology.
[88] G. Ott,et al. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. , 1995, Vaccine.
[89] M. Powell,et al. Vaccine Design , 1995, Pharmaceutical Biotechnology.
[90] J. Kahn,et al. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. , 1994, The Journal of infectious diseases.
[91] B. Savarese,et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes , 1994, The Lancet.
[92] D. O’hagan. Novel Delivery Systems for Oral Vaccines , 1994 .
[93] D. O'hagan,et al. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. , 1994, Immunology.
[94] C. Kensil,et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. , 1994, Vaccine.
[95] Seamus J. Martin,et al. Immunization of human HIV‐seronegative volunteers with recombinant p17/p24: Ty virus‐like particles elicits HIV‐1 p24‐specific cellular and humoral immune responses , 1993, AIDS.
[96] M. Reddish,et al. Immune Responses of Mice and Human Breast Cancer Patients following Immunization with Synthetic Sialyl‐Tn Conjugated to KLH Plus Detox Adjuvant , 1993, Annals of the New York Academy of Sciences.
[97] A. Gettie,et al. Protection against vaginal SIV transmission with microencapsulated vaccine. , 1993, Science.
[98] S. Davis,et al. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles. , 1993, Vaccine.
[99] G. Poste,et al. New Generation Vaccines , 1993, NATO ASI Series.
[100] C. Alving,et al. Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. , 1992, Biochimica et biophysica acta.
[101] D. Rahman,et al. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. , 1992, Immunology.
[102] G. Gustafson,et al. Bacterial cell wall products as adjuvants: early interferon gamma as a marker for adjuvants that enhance protective immunity. , 1992, Research in immunology.
[103] S. Davis,et al. Controlled release microparticles for vaccine development. , 1991, Vaccine.
[104] D. Pisetsky,et al. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. , 1991, Journal of immunology.
[105] Eldridge,et al. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies , 1991, Infection and immunity.
[106] S. Romagnani. Human TH1 and TH2 subsets: doubt no more. , 1991, Immunology today.
[107] D. Rahman,et al. Biodegradable microparticles as controlled release antigen delivery systems. , 1991, Immunology.
[108] T. Mosmann,et al. The role of IL-10 in crossregulation of TH1 and TH2 responses. , 1991, Immunology today.
[109] Gary J. Nabel,et al. New Generation Vaccines , 1990 .
[110] Thomas R. Tice,et al. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches , 1990 .
[111] G. Gregoriadis. Immunological adjuvants: a role for liposomes. , 1990, Immunology today.
[112] T. Mosmann,et al. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies , 1987, The Journal of experimental medicine.
[113] W. Paul,et al. Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.
[114] A. Bird. CpG islands as gene markers in the vertebrate nucleus , 1987 .
[115] R. Coffman,et al. Two types of mouse helper T-cell clone Implications for immune regulation. , 1987, Immunology today.
[116] A. Allison,et al. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. , 1986, Journal of immunological methods.
[117] Y. Fujisawa,et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. , 1984, Journal of the National Cancer Institute.
[118] B D Hall,et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast , 1982, Nature.